Search

Your search keyword '"Yin, Yongmei"' showing total 917 results

Search Constraints

Start Over You searched for: Author "Yin, Yongmei" Remove constraint Author: "Yin, Yongmei" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
917 results on '"Yin, Yongmei"'

Search Results

2. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

7. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study

14. Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: Clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts.

16. A phase 1 study of liposomal irinotecan in patients with advanced breast cancer.

17. Anti-TNFR2 monoclonal antibody LBL-019 in patients with advanced malignant tumors: A phase I, first-in-human, open-label, multicenter, dose escalation Study.

18. Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.

22. CACA Guidelines for Holistic Integrative Management of Breast Cancer

25. Tyrosine kinase inhibitors in HER2‐positive metastatic breast cancer with trastuzumab emtansine resistance: insights from a multicenter retrospective real‐world study.

26. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

31. Efficacy, Safety, and Population Pharmacokinetics of MW032 Compared With Denosumab for Solid Tumor–Related Bone Metastases

35. Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial

38. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study

40. The war between the immune system and the tumor - using immune biomarkers as tracers.

42. Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2‐Positive Breast Cancer.

44. Suboptimal declines and delays in early breast cancer treatment after COVID-19 quarantine restrictions in China: A national survey of 8397 patients in the first quarter of 2020

47. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study

48. OR98 UPDATED OVERALL SURVIVAL (OS) OUTCOMES FROM THE PHASE 3 PHOEBE TRIAL OF PYROTINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER

Catalog

Books, media, physical & digital resources